n INTRODUCTION I diopathic inflammatory myopathies (IIM), including polymyositis (PM) and dermatomyositis (DM), are heterogeneous diseases occurring with proximal symmetrical muscle weakness, increased serum muscle enzymes, inflammatory infiltrates on muscle biopsy and specific skin lesions (1, 2) . IIM can also be sub-classified on the basis of the auto-antibody profile. Among myositis-specific auto-antibodies, those targeting aminoacyl-tRNA synthetases have been associated with a specific clinical phenotype, the so-called anti-synthetase syndrome (ASS), anti-Jo-1 being the most frequent antibody (3) (4) (5) . Even if the pathogenesis of IIM is not yet fully understood, many authors suggest that an active role may be played by cytokines found both in muscle tissue and peripheral blood, including interleukin (IL)-15, IL-17, IL-6, IL-10, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and MIP-1β (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Recently, IL-15 and IL-17 have emerged as candidate mediators of induction/expansion of the pro-inflammatory cytokine cascade in IIM, and systemic or muscle production of IL-15 and IL-17 has been demonstrated in patients affected by IIM (20) (21) (22) . IL-15, originally identified as T cell activating factor, is widely expressed in human tissues including skeletal muscle, but it is rarely detected in healthy conditions. It participates in the development
The aim of this study was to assess the serum levels of interleukin (IL)-15 and IL-17 in patients with idiopathic inflammatory myopathies (IIM) and correlate them with IL-6, IL-10, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), MIP-1β levels. Possible correlations with disease activity parameters were also evaluated. Sera from 14 polymyositis (PM), 10 dermatomyositis (DM), 7 anti-synthetase syndrome new onset patients and 19 healthy controls (HCs) were analyzed by multiplex immunoassay. Sera from 19 patients were analyzed after 5 months median follow-up. All patients underwent physical examination, the 5-points manual muscle test (MMT), the health assessment questionnaire and serum creatine kinase measurement. All patients received glucocorticoids, and 13 were taking also immunosuppressive therapy. At baseline, serum levels of IL-15, IL-17, MCP-1 and MIP-1β were significantly higher in IIM patients than in HCs. IL-17 serum levels were directly correlated with disease duration (r=0.39, P=0.02), while a significant inverse correlation was detected between IL-17 levels and MMT scores (r=-0.4, P=0.02). The highest IL-15 levels were present in DM patients (P=0.02 vs PM). The most striking finding was the strong correlation between IL-15 and IL-17 levels (r=0.60, P=0.0001), and this correlation was even stronger in DM patients (r=0.82, P=0.006). The strong correlation between IL-15 and IL-17 in IIM patients, and especially in DM, suggests that there may be a interplay between the two cytokines in the pathogenesis of myositis. Further studies of larger patient cohorts and muscle biopsies are needed to confirm these preliminary data. of natural killer cells, binding its unique receptor shared with IL-2. IL-15 has been reported to be increased in autoimmune or inflammatory diseases, such as in the synovial fluid or membrane of rheumatoid arthritis (RA) patients (23) (24) (25) . In PM and DM, IL-15 and its receptor have been found in muscle tissue, and high serum levels have also been detected (11, 20, 22) . It is well known that the T helper 17 pathway is one of the most important mechanisms inducing and maintaining chronic inflammation (26 Table I Concerning IL-6 and IL-10, no statistically significant differences between IIM patients and HCs have been found. Comparing cytokines serum levels of IIM patients at baseline and follow-up, no significant differences were found. We assessed whether the serum levels of all cytokines were influenced by glucocorticoids and the clinical parameters at baseline (Tab. III). We found a direct corre- (Fig. 2) . Finally, we searched for possible relationships among cytokines in all IIM patients at baseline. Because of the correlation of IL-17 with disease duration, the latter confounder was removed by applying partial correlation analysis. The most striking finding was the strong correlation between IL-15 and IL-17 levels (r=0.60, P=0.0001).
Statistical analysis
In patients affected by DM, the correlation between IL-15 and IL-17 was found to be even stronger (r=0.82, P=0.006), as shown in Figure 3 . No correlation between IL-15 and IL-17 in HCs was found n DISCUSSION
In this study we aimed at evaluating the serum levels of IL-15 and IL-17 in 14 PM, 10 DM and 7 ASS Jo1+ve patients treated in a standard care rheumatology setting, at baseline and after a median follow-up period of 5 months. IL-15 and IL-17 serum levels were also correlated with IL-6, IL-10, MCP-1, MIP-1α, MIP-1β serum levels. In addition, we assessed possible correlations between all cytokines serum levels and 5-MMT, HAQ scores and CK concentration.
In agreement with the literature, IIM patients showed higher levels of MCP-1, MIP-1β, IL-15 and IL-17 than HC (6, 11, 21, 27, (34) (35) (36) (37) (38) (39) . MCP-1 has already been detected either in sera or in muscle tissue (6, (35) (36) (37) . While DMARDs did not affect cytokines levels, we found a direct correlation between glucorticoid dosage and IL-10 or MIP-1α levels.
In agreement with many reports, high levels of IL-15 and IL-17 were detected in IIM patients (11, 16, 20-22, 27, 39) . Unlike a previous study that reported high IL-17 serum levels in early stage disease (27) , we found a direct correlation between IL-17 and disease duration. However, differences in serum sampling can account for this discrepancy. We observed, for the first time in IIM patients, that IL-15 and IL-17 serum levels were strongly correlated and that this correlation was not affected by disease duration and therapy.
To date, few and discordant reports concerning comparisons between cytokine serum levels among the different subsets of IIM have been published (16, 40) . Instead, our study clearly showed that IL-15 serum levels differed significantly among the clinical subsets, being higher in adult DM than PM. In DM the degree of association between IL-15 and IL-17 was even stronger. (43) . In IIM muscle, IL-15 is secreted by myoblasts following an interaction between CD40 expressed on myoblasts and CD40L expressed on infiltrating T cells (38) . However, the expression of IL-15 may depend on the grade of differentiation of the muscle fibers (22) . IL-15 synthesis has been found to be increased in PM and DM muscle biopsies (20) , and circulating IL-15 levels were higher in patients than in controls (11, 39) . Recently, IL-15 expression has been demonstrated in macrophages in muscle biopsies from patients with IIM, but not in T cells (22) . Moreover, the IL-15 receptor (IL-15R) has been observed in muscle tissue (20) , in particular in mononuclear cell infiltrates and endothelial cells (22) . IL-17, produced by T cells, plays an important role in host defense, inflammation, and autoimmunity (26) , and its expression is increased in inflammatory tissues, including IIM (21) . Since the identification of Th17 cells in inflamed muscle tissue, IL-17 has been proposed as a co-actor in the immune response that could lead to muscle destruction, and higher serum levels of IL-17 and IL-23, the IL-17 main inducer, have been observed in the sera of PM/DM patients than in HCs (27) . Consistently, we found a strong correlation between IL-17 and IL-15 serum levels in IIM patients and we hypothesize that also in IIM IL-15 acts as a strong inducer/regulator of IL-17 synthesis, even if muscle tissue findings are lacking. In addition, exploring the serum levels of IL-15 and IL-17 in patients with amyopathic DM may help the comprehension of their role in the pathogenesis of IIM. An inverse correlation between baseline IL-17 serum levels and muscle strength, as measured by the 5-MMT, was observed in our study, suggesting that IL-17 might be a potential biomarker of clinical outcome. However, these findings should be interpreted with caution as MMT score did not substantially vary over time in contrast to IL-17 levels.
In addition, follow-up data are available in a small subpopulation and need to be confirmed in larger studies. We did not find a significant correlation between IL-15 serum levels and the 5-MMT, while a negative correlation between IL-15 muscle expression and the myositis function index has already been reported, although different samples and muscle strength measurements were used in the two studies (22) . The data we have obtained need to be confirmed in larger cohorts of IIM patients. Our future proposal is to investigate IL-15 and IL-17 serum levels at the disease onset before starting any treatment. A better understanding of the IL-15 and IL-17 interplay, especially in the DM subset, may provide further insights into the pathogenesis of muscle damage and identify novel therapeutic targets.
Key messages -IL-15 and IL-17 serum levels are strongly correlated in patients with IIM, especially in DM.
-Higher IL-15 serum levels have been found in DM than in PM.
-A significant inverse correlation has been found between IL-17 levels and MMT scores. 
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